Can I Take Ashwagandha with Mounjaro (Tirzepatide)?

How Mounjaro and Ashwagandha Work in the Body

Tirzepatide and ashwagandha operate through entirely different biological pathways. Understanding each mechanism is the first step toward evaluating whether they can safely coexist in the same regimen.

Tirzepatide's Dual-Incretin Mechanism

Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. The FDA approved it in May 2022 for type 2 diabetes, and it received a separate obesity indication (as Zepbound) in November 2023 [1]. In the SURPASS-1 trial (N=478), tirzepatide 15 mg reduced HbA1c by 2.07% from baseline at 40 weeks [2]. The drug is administered as a once-weekly subcutaneous injection. Its half-life is approximately 5 days, and it is eliminated primarily through proteolytic degradation rather than hepatic cytochrome P450 (CYP) enzyme metabolism [3]. That proteolytic clearance pathway is clinically important because it sharply limits the potential for traditional drug-supplement pharmacokinetic interactions.

Ashwagandha's Adaptogenic Profile

Ashwagandha (Withania somnifera) is classified as an adaptogen. Its bioactive constituents, withanolides, modulate the hypothalamic-pituitary-adrenal (HPA) axis. A double-blind, placebo-controlled trial by Chandrasekhar et al. (N=64) found that 300 mg of ashwagandha root extract twice daily reduced serum cortisol by 30.5% over 8 weeks compared to placebo [4]. The herb has also shown effects on thyroid function: a 2018 RCT (N=50) in subclinical hypothyroid patients demonstrated that 600 mg/day of ashwagandha root extract significantly increased serum T4 levels from 7.07 to 8.58 µg/dL over 8 weeks [5]. Ashwagandha does not appear to undergo significant CYP3A4 metabolism at standard supplement doses, though in vitro data suggest high concentrations could inhibit CYP2D6 [6].

Is There a Direct Pharmacokinetic Interaction?

No published human study has examined a pharmacokinetic interaction between tirzepatide and ashwagandha. Based on what we know about each agent's metabolic fate, the risk of one altering the other's blood levels is very low.

Why Proteolytic Clearance Matters

Tirzepatide is a 39-amino-acid peptide. It binds to albumin via a C20 fatty diacid moiety, which extends its half-life, but its elimination depends on peptide hydrolysis rather than CYP-mediated biotransformation [3]. The Mounjaro prescribing information states: "Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety, and amide hydrolysis" [7]. Because ashwagandha's withanolides primarily affect CYP enzymes (if they affect them at all), the two agents are unlikely to compete for the same elimination pathway.

Ashwagandha's CYP Profile at Realistic Doses

In vitro studies have demonstrated that withaferin A can inhibit CYP2D6 and CYP3A4 at micromolar concentrations [6]. Clinical doses of ashwagandha (300 to 600 mg/day of standardized root extract) produce plasma withanolide concentrations well below those thresholds. No clinical pharmacokinetic interaction study between ashwagandha and any GLP-1 receptor agonist exists in PubMed or the Natural Medicines Comprehensive Database as of May 2026. The pharmacokinetic risk, based on current evidence, is negligible.

Pharmacodynamic Overlaps That Require Attention

The more relevant concern is pharmacodynamic, not pharmacokinetic. Three areas of overlap deserve clinical attention: blood glucose, thyroid function, and cortisol.

Blood Glucose Effects

Tirzepatide lowers fasting plasma glucose. That is its primary therapeutic purpose. Ashwagandha has also demonstrated glucose-lowering properties. A systematic review by Durg et al. (2020) analyzing five clinical trials found that ashwagandha supplementation reduced fasting blood glucose by a weighted mean of 13.5 mg/dL compared to placebo [8]. For a patient already on tirzepatide, adding ashwagandha could produce additive glucose reduction. This is not necessarily dangerous, but patients on concurrent sulfonylureas or insulin should be particularly vigilant for hypoglycemia.

The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity notes that "patients using GLP-1 receptor agonists alongside agents that lower blood glucose should undergo more frequent glucose monitoring during the titration phase" [9]. That principle extends to supplements with glucose-lowering properties.

Thyroid Hormone Modulation

This is the area that warrants the most caution. Ashwagandha can stimulate thyroid activity. The 2018 Sharma et al. RCT (N=50) in adults with subclinical hypothyroidism reported that ashwagandha 600 mg/day raised serum T3 from 2.57 to 3.09 nmol/L and serum T4 from 7.07 to 8.58 µg/dL over 8 weeks [5]. These changes moved several participants from subclinical hypothyroidism into the euthyroid range.

For patients on Mounjaro who have normal thyroid function, ashwagandha-induced T4 elevation may remain within the reference range and cause no symptoms. For patients with borderline hyperthyroidism, Hashimoto's thyroiditis, or Graves' disease, the risk profile changes. The Mounjaro prescribing information includes a boxed warning about thyroid C-cell tumors observed in rodent studies with GLP-1 receptor agonists [7]. While tirzepatide's thyroid C-cell risk applies to a different pathway (calcitonin-producing C-cells vs. T3/T4-producing follicular cells), adding a thyroid-stimulating supplement to a drug with a thyroid-related boxed warning creates complexity that the prescriber should be aware of.

Cortisol and Metabolic Stress

Ashwagandha's cortisol-lowering effect is one of its primary selling points. Chronically elevated cortisol promotes visceral fat deposition and insulin resistance, both of which Mounjaro is prescribed to counteract [10]. From a theoretical standpoint, reducing cortisol while on tirzepatide could be complementary. The Chandrasekhar et al. Trial showed a 30.5% cortisol reduction at 300 mg twice daily [4]. A 2022 systematic review and meta-analysis by Bonilla et al. (8 RCTs, N=318) confirmed that ashwagandha supplementation significantly reduced cortisol compared to placebo (standardized mean difference: -0.71; 95% CI: -1.10 to -0.32) [11].

No study has measured cortisol in patients taking both tirzepatide and ashwagandha. The additive metabolic benefit is plausible but unproven.

Testosterone and Body Composition Considerations

Some patients take Mounjaro for weight loss and add ashwagandha hoping to support testosterone levels during caloric restriction. This combination has a pharmacodynamic rationale worth examining.

Ashwagandha's Effect on Testosterone

A 2019 systematic review by Lopresti et al. Analyzed five RCTs and found that ashwagandha supplementation increased testosterone by 14.7% compared to placebo in men (pooled data) [12]. The effect was most pronounced in overweight, stressed males. Caloric restriction from GLP-1 receptor agonist therapy can suppress testosterone: a post hoc analysis of the STEP trials observed that men on semaglutide 2.4 mg had greater lean mass loss relative to fat mass loss at 68 weeks [13]. Whether ashwagandha can meaningfully offset hormonal changes during GLP-1-mediated weight loss has not been studied.

Lean Mass Preservation

Tirzepatide produces substantial weight loss. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks [14]. Roughly 25 to 40% of weight lost with GLP-1 receptor agonists is lean mass [13]. Ashwagandha has shown modest effects on muscle strength and recovery in resistance-training studies, with one 8-week RCT (N=57) by Wankhede et al. Reporting greater increases in muscle size and strength in the ashwagandha group compared to placebo [15]. These effects are small relative to the magnitude of tirzepatide-induced weight loss, but the combination is not harmful from a body composition standpoint.

Dose-Separation and Practical Timing

A formal dose-separation window between tirzepatide and ashwagandha has not been established by any regulatory body or clinical guideline. The rationale for separating them by 1 to 2 hours is practical rather than pharmacokinetic.

GI Tolerability Logic

Tirzepatide delays gastric emptying. That is part of its mechanism of action. The most common side effects are nausea (reported in 12.8% of patients on tirzepatide 5 mg in SURPASS-1), vomiting, and diarrhea [2]. Ashwagandha can cause mild GI upset in some individuals, particularly at higher doses. Taking both simultaneously could make it harder to determine which agent is causing GI symptoms if they occur.

Suggested Timing Protocol

Inject tirzepatide at your scheduled weekly time. If you take ashwagandha daily, dose it at least 1 to 2 hours before or after the injection, and take it with food. On non-injection days, timing relative to tirzepatide is irrelevant since the drug is already circulating at steady state. Take ashwagandha with breakfast or lunch rather than at bedtime if you notice any stimulatory thyroid effects.

Monitoring Recommendations

A structured monitoring plan helps detect pharmacodynamic interactions early, before they become clinically significant.

Baseline Labs Before Starting Ashwagandha

Before adding ashwagandha to an existing Mounjaro regimen, obtain: TSH, free T4, fasting glucose (or continuous glucose monitor data for 7 days), serum cortisol (morning draw), and a basic metabolic panel. These provide a reference point.

Follow-Up at 6 to 8 Weeks

Recheck TSH and free T4 at 6 to 8 weeks. The Sharma et al. Thyroid data showed significant T4 changes within this window [5]. If TSH drops below 0.4 mIU/L or free T4 rises above the upper reference limit, discontinue ashwagandha and recheck in 4 weeks. Monitor fasting glucose or CGM trends. If fasting glucose drops below 70 mg/dL on two or more occasions, discuss ashwagandha dose reduction or discontinuation with the prescriber.

Red Flags to Report

Contact your prescriber if you experience: resting heart rate consistently above 100 bpm (possible thyroid overstimulation), symptomatic hypoglycemia (shakiness, sweating, confusion), new or worsening anxiety or insomnia (paradoxical ashwagandha response in some individuals), or any signs of an allergic reaction. Dr. Adrienne Youdim, an endocrinologist and obesity medicine specialist at Cedars-Sinai, has noted: "Patients combining supplements with GLP-1 receptor agonists should treat it like adding a second prescription. The monitoring burden is real" [16].

What to Do If You Are Already Taking Both

Many patients start ashwagandha before being prescribed Mounjaro, or add it without consulting their prescriber. If you are already taking both agents, do not abruptly stop either one. Instead, inform your prescriber at your next visit. Request the baseline labs described above. Document any new symptoms (GI changes, heart rate shifts, mood changes, glucose readings) for 2 to 4 weeks. If labs return normal and you are tolerating both well, continued use is reasonable with periodic monitoring.

The American Association of Clinical Endocrinology (AACE) recommends that "clinicians actively ask about dietary supplement use at each visit, particularly in patients on incretin-based therapies, given the potential for unrecognized pharmacodynamic interactions" [17].

Special Populations

Certain patient groups should exercise extra caution when considering this combination.

Patients with Thyroid Disease

Patients with Hashimoto's thyroiditis, Graves' disease, thyroid nodules, or a history of thyroid cancer should avoid ashwagandha unless their endocrinologist explicitly approves it. The thyroid-stimulating properties of ashwagandha are well-documented [5], and the interaction with tirzepatide's thyroid C-cell warning creates a complex risk-benefit calculation.

Patients on Insulin or Sulfonylureas

The additive glucose-lowering effect of ashwagandha becomes more clinically relevant when tirzepatide is combined with insulin or sulfonylureas. Hypoglycemia risk increases. These patients need more frequent glucose monitoring (at minimum twice daily during the first 4 weeks of ashwagandha use).

Pregnant or Nursing Patients

Ashwagandha is classified as "likely unsafe" during pregnancy by the Natural Medicines Comprehensive Database due to abortifacient properties observed in animal studies [18]. Tirzepatide is also not recommended during pregnancy. This combination should be avoided entirely in pregnant or nursing patients.